Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19

• Published in: Med (New York, N.Y. : Online) Vol. 5; no. 1; pp. 42 - 61.e23
• Main Authors: Mao, Long, Shaabani, Namir, Zhang, Xiaoying, Jin, Can, Xu, Wanhong, Argent, Christopher, Kushnareva, Yulia, Powers, Colin, Stegman, Karen, Liu, Jia, Xie, Hui, Xu, Changxu, Bao, Yimei, Xu, Lijun, Zhang, Yuren, Yang, Haigang, Qian, Shengdian, Hu, Yong, Shao, Jianping, Zhang, Can, Li, Tingting, Li, Yi, Liu, Na, Lin, Zhenhao, Wang, Shanbo, Wang, Chao, Shen, Wei, Lin, Yuanlong, Shu, Dan, Zhu, Zhenhong, Kotoi, Olivia, Kerwin, Lisa, Han, Qing, Chumakova, Ludmila, Teijaro, John, Royal, Mike, Brunswick, Mark, Allen, Robert, Ji, Henry, Lu, Hongzhou, Xu, Xiao
• Format: Journal Article
• Language: English
• Published: 12.01.2024

Oral antiviral drugs with improved antiviral potency and safety are needed to address current challenges in clinical practice for treatment of COVID-19, including the risks of rebound, drug-drug interactions, and emerging resistance.BACKGROUNDOral antiviral drugs with improved antiviral potency and...